HilleVax, Inc., (HLVX) News
Filter HLVX News Items
HLVX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest HLVX News From Around the Web
Below are the latest news stories about HILLEVAX INC that investors may wish to consider to help them evaluate HLVX as an investment opportunity.
3 US Penny Stocks With Market Caps Under $100MAs U.S. stocks experience fluctuations amid anticipation of key inflation data and interest rate decisions, investors are keenly observing market movements for potential opportunities. Penny stocks, a term that may seem outdated, continue to capture attention due to their affordability and growth potential, particularly when backed by strong financials. These smaller or newer companies can offer unique value propositions that larger firms might overlook, making them intriguing options for... |
HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for th |
Rave Restaurant Group And 2 Other Promising US Penny StocksAs the U.S. stock market experiences a rise, buoyed by gains in the technology sector and investor focus on the upcoming presidential election, attention is also drawn to smaller investment opportunities. Though often considered a relic from past trading days, "penny stocks" continue to represent potential for significant returns when they are backed by strong financials. This article will explore three such penny stocks that stand out for their balance sheet strength and growth potential in... |
What Makes HilleVax (HLVX) a New Buy StockHilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2024 and highlighted recent progress. Recent |
HilleVax slashes workforce by 40% after norovirus vaccine trial failureHilleVax’s norovirus vaccine HIL-214 failed to meet key endpoints in its Phase IIb trial in infants, prompting the company to let go of 41 employees. |
HilleVax Announces Reduction in ForceBOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce reduction to reduce its operating expenses. The reduction of approximately 41 employees, or approximately 40% of the company’s workforce, is intended to preserve cash while maintaining core capabilities as the company explores the potential for continued development of its HIL-214 and HIL-216 noro |
After Plunging -86.93% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax (HLVX)The heavy selling pressure might have exhausted for HilleVax (HLVX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a TurnaroundHilleVax (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study FailureIDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates. |